# Vascular Impact of Dapagliflozin in CKD Patients (DAPAVASC)

> **NCT04930549** · PHASE2 · COMPLETED · sponsor: **University Hospital, Rouen** · enrollment: 32 (actual)

## Conditions studied

- Renal Insufficiency, Chronic

## Interventions

- **DRUG:** Dapagliflozin 10Mg Tab
- **DRUG:** Placebo
- **PROCEDURE:** impedance cardiography
- **PROCEDURE:** Applanation tonometry
- **PROCEDURE:** post-ischemic hyperemia of forearm
- **PROCEDURE:** haemodynamics parameters

## Key facts

- **NCT ID:** NCT04930549
- **Lead sponsor:** University Hospital, Rouen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-18
- **Primary completion:** 2024-09-23
- **Final completion:** 2024-09-23
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2026-02-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04930549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04930549, "Vascular Impact of Dapagliflozin in CKD Patients (DAPAVASC)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04930549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*